Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Investor5876on Oct 06, 2024 12:22pm
347 Views
Post# 36255117

PR and Partnership

PR and PartnershipONC's latest press release is impressive. 

Unlike many of ONC's past PR's, this one is very clearly written and unambiguous. 

It is also encouraging. And the promise comes from achievable honest milestones (very different from what we have seen in recent years).

The only outstanding question is financing. ONC does not currently have the funds. 

I believe ONC is within weeks of announcing a major partnership. Three reasons for this:

1. The BC data are compelling enough for a major pharma to make a move. 

2. Even with a reverse split and large capital raise, ONC will not be able to sufficiently finance a 180 patient tiral. 

3. ONC is well aware they do not have the in house capabilities to proceed with a large registration enabling trial. 

Best of luck. IMO This is an excellent entry point for any investor new to the story. 
<< Previous
Bullboard Posts
Next >>